Trial Profile
A single centre, proof-of-concept clinical study for SM-88 in advanced metastatic cancer patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Apr 2019
Price :
$35
*
At a glance
- Drugs Racemetyrosine (Primary) ; Racemetyrosine (Primary) ; Phenytoin; Sirolimus
- Indications Advanced breast cancer; Appendiceal cancer; Biliary cancer; Cancer; Colon cancer; Liver cancer; Lung cancer; Pancreatic cancer; Prostate cancer; Thyroid cancer; Tongue cancer
- Focus First in man; Proof of concept; Therapeutic Use
- Sponsors Tyme Technologies
- 30 Mar 2019 Results evaluating safetyn and efficacy of SMK therapy in subjects with advanced metastatic cancers published in the Investigational New Drugs
- 12 Jun 2018 Details data and results of analyses from this and a compassionate use study (CT profile 700292463) (n=83) presented in a Tyme Technologies media release.
- 05 Jun 2018 Results (n=25) of retrospective chart review of metastatic breast cancer (mBC) subjects treated with SM-88 (aka SMK) under Phase I or compassionate use programs, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.